Localized hippocampus measures are associated with Alzheimer pathology and cognition independent of total hippocampal volume.

Department of Neurology, School of Medicine, University of California, Davis, Davis, CA, USA.
Neurobiology of aging (Impact Factor: 5.94). 12/2011; 33(6):1124.e31-41. DOI: 10.1016/j.neurobiolaging.2011.08.016
Source: PubMed

ABSTRACT Hippocampal injury in the Alzheimer's disease (AD) pathological process is region-specific and magnetic resonance imaging (MRI)-based measures of localized hippocampus (HP) atrophy are known to detect region-specific changes associated with clinical AD, but it is unclear whether these measures provide information that is independent of that already provided by measures of total HP volume. Therefore, this study assessed the strength of association between localized HP atrophy measures and AD-related measures including cerebrospinal fluid (CSF) amyloid beta and tau concentrations, and cognitive performance, in statistical models that also included total HP volume as a covariate. A computational technique termed localized components analysis (LoCA) was used to identify 7 independent patterns of HP atrophy among 390 semiautomatically delineated HP from baseline magnetic resonance imaging of participants in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Among cognitively normal participants, multiple measures of localized HP atrophy were significantly associated with CSF amyloid concentration, while total HP volume was not. In addition, among all participants, localized HP atrophy measures and total HP volume were both independently and additively associated with CSF tau concentration, performance on numerous neuropsychological tests, and discrimination between normal, mild cognitive impairment (MCI), and AD clinical diagnostic groups. Together, these results suggest that regional measures of hippocampal atrophy provided by localized components analysis may be more sensitive than total HP volume to the effects of AD pathology burden among cognitively normal individuals and may provide information about HP regions whose deficits may have especially profound cognitive consequences throughout the AD clinical course.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer’s Disease (AD) is characterized by a stereotypical spatial pattern of hippocampus (HP) atrophy over time, but reliable and precise measurement of localized longitudinal change to individual HP in AD have been elusive. We present a method for quantifying subject-specific spatial patterns of longitudinal HP change that aligns serial HP surface pairs together, cuts slices off the ends of the HP that were not shared in the two delineations being aligned, estimates weighted correspondences between baseline and follow-up HP, and finds a concise set of localized spatial change patterns that explains HP changes while down-weighting HP surface points whose estimated changes are biologically implausible. We tested our method on a synthetic HP change dataset as well as a set of 320 real elderly HP measured at 1-year intervals. Our results suggests that the proposed steps reduce the amount of implausible HP changes indicated among individual HP, increase the strength of association between HP change and cognitive function related to AD, and enhance the estimation of reliable spatially-localized HP change patterns.
    Computer Vision and Image Understanding 09/2013; 117(9):1128–1137. · 1.36 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective. Memory accuracy is a major problem in human disease and is the primary factor that defines Alzheimer's, ageing and dementia resulting from impaired hippocampal function in the medial temporal lobe. Development of a hippocampal memory neuroprosthesis that facilitates normal memory encoding in nonhuman primates (NHPs) could provide the basis for improving memory in human disease states. Approach. NHPs trained to perform a short-term delayed match-to-sample (DMS) memory task were examined with multi-neuron recordings from synaptically connected hippocampal cell fields, CA1 and CA3. Recordings were analyzed utilizing a previously developed nonlinear multi-input multi-output (MIMO) neuroprosthetic model, capable of extracting CA3-to-CA1 spatiotemporal firing patterns during DMS performance. Main results. The MIMO model verified that specific CA3-to-CA1 firing patterns were critical for the successful encoding of sample phase information on more difficult DMS trials. This was validated by the delivery of successful MIMO-derived encoding patterns via electrical stimulation to the same CA1 recording locations during the sample phase which facilitated task performance in the subsequent, delayed match phase, on difficult trials that required more precise encoding of sample information. Significance. These findings provide the first successful application of a neuroprosthesis designed to enhance and/or repair memory encoding in primate brain.
    Journal of Neural Engineering 11/2013; 10(6):066013. · 3.42 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In recent years, numerous laboratories and consortia have used neuroimaging to evaluate the risk for and progression of Alzheimer's disease (AD). The Alzheimer's Disease Neuroimaging Initiative is a longitudinal, multicenter study that is evaluating a range of biomarkers for use in diagnosis of AD, prediction of patient outcomes, and clinical trials. These biomarkers include brain metrics derived from magnetic resonance imaging (MRI) and positron emission tomography scans as well as metrics derived from blood and cerebrospinal fluid. We focus on Alzheimer's Disease Neuroimaging Initiative studies published between 2011 and March 2013 for which structural MRI was a major outcome measure. Our main goal was to review key articles offering insights into progression of AD and the relationships of structural MRI measures to cognition and to other biomarkers in AD. In Supplement 1, we also discuss genetic and environmental risk factors for AD and exciting new analysis tools for the efficient evaluation of large-scale structural MRI data sets such as the Alzheimer's Disease Neuroimaging Initiative data.
    Biological psychiatry 11/2013; · 8.93 Impact Factor

Full-text (5 Sources)

Available from
Jul 2, 2014